Roche's Blood-Cancer Drug Deal with Nurix Complements Strengths -- Market Talk

Dow Jones06-08

0723 GMT - Roche's collaboration with Nurix Therapeutics on blood-cancer drug bexobrutideg complements its existing strengths in hematology, Vontobel analyst Stefan Schneider says in a research note. It also provides a cross-therapeutic opportunity to extend the Swiss drugmaker's pipeline's reach in immunology and neurology, the analyst adds. The blood-cancer drug is Nurix's investigational tyrosine kinase degrader that eliminates disease-causing proteins. The drug has the potential to overcome existing treatment-emergent resistance mutations, Schneider adds. Shares trade 0.5% lower at 325.4 Swiss francs. (nina.kienle@wsj.com)

(END) Dow Jones Newswires

June 08, 2026 03:23 ET (07:23 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2641011651?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-08 15:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2641011651","market":"nz","top_or_hot":-1,"title":"Roche's Blood-Cancer Drug Deal with Nurix Complements Strengths -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0723 GMT - Roche's collaboration with <a href=\"https://laohu8.com/S/NRIX\">Nurix Therapeutics</a> on blood-cancer drug bexobrutideg complements its existing strengths in hematology, Vontobel analyst Stefan Schneider says in a research note. It also provides a cross-therapeutic opportunity to extend the Swiss drugmaker's pipeline's reach in immunology and neurology, the analyst adds. The blood-cancer drug is Nurix's investigational tyrosine kinase degrader that eliminates disease-causing proteins. The drug has the potential to overcome existing treatment-emergent resistance mutations, Schneider adds. Shares trade 0.5% lower at 325.4 Swiss francs. (nina.kienle@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 08, 2026 03:23 ET (07:23 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche's Blood-Cancer Drug Deal with Nurix Complements Strengths -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche's Blood-Cancer Drug Deal with Nurix Complements Strengths -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-08 15:23</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0723 GMT - Roche's collaboration with <a href=\"https://laohu8.com/S/NRIX\">Nurix Therapeutics</a> on blood-cancer drug bexobrutideg complements its existing strengths in hematology, Vontobel analyst Stefan Schneider says in a research note. It also provides a cross-therapeutic opportunity to extend the Swiss drugmaker's pipeline's reach in immunology and neurology, the analyst adds. The blood-cancer drug is Nurix's investigational tyrosine kinase degrader that eliminates disease-causing proteins. The drug has the potential to overcome existing treatment-emergent resistance mutations, Schneider adds. Shares trade 0.5% lower at 325.4 Swiss francs. (nina.kienle@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 08, 2026 03:23 ET (07:23 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03165","symbol_name":"华夏欧优股对冲","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2641011651","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2641011651","pubTimestamp":1780903380,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0723 GMT - Roche's collaboration with Nurix Therapeutics on blood-cancer drug bexobrutideg complements its existing strengths in hematology, Vontobel analyst Stefan Schneider says in a research note. It also provides a cross-therapeutic opportunity to extend the Swiss drugmaker's pipeline's reach in immunology and neurology, the analyst adds. The blood-cancer drug is Nurix's investigational tyrosine kinase degrader that eliminates disease-causing proteins. The drug has the potential to overcome existing treatment-emergent resistance mutations, Schneider adds. Shares trade 0.5% lower at 325.4 Swiss francs. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03165":"华夏欧优股对冲","RHHBY":"罗氏控股","BK4007":"制药"},"translate_title":"罗氏与Nurix的血癌药物交易优势互补——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03165":0.6,"RHHBY":0.9},"content_text":"0723 GMT - Roche's collaboration with Nurix Therapeutics on blood-cancer drug bexobrutideg complements its existing strengths in hematology, Vontobel analyst Stefan Schneider says in a research note. It also provides a cross-therapeutic opportunity to extend the Swiss drugmaker's pipeline's reach in immunology and neurology, the analyst adds. The blood-cancer drug is Nurix's investigational tyrosine kinase degrader that eliminates disease-causing proteins. The drug has the potential to overcome existing treatment-emergent resistance mutations, Schneider adds. Shares trade 0.5% lower at 325.4 Swiss francs. (nina.kienle@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 08, 2026 03:23 ET (07:23 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2641011651","isCrawlerRequest":true}